Hassan Shahryar MD, FACP
@hassanshahryar.bsky.social
Medical Oncologist & Hematologist • Aga Khan Uni & PennState Hershey Alum • LGP ESMO Asia 22 • http://ssmc.ae • Abu Dhabi UAE •
Historically N2 disease carried a poor prognosis however as shown in Aegean trial IO can help overcome this poor prognosis. So i guess more patients can benefit from neo/peri op chemo-IO approach. But should we be routinely offering conversion surgey now ?
December 4, 2024 at 4:19 PM
Historically N2 disease carried a poor prognosis however as shown in Aegean trial IO can help overcome this poor prognosis. So i guess more patients can benefit from neo/peri op chemo-IO approach. But should we be routinely offering conversion surgey now ?